Valneva: Valneva, a specialty vaccine company, today announced that the U.S. Food and Drug Administration (FDA) has approved IXCHIQ, Valneva's single-dose, live-attenuated vaccine indicated for the prevention of disease caused by chikungunya virus (CHIKV) in individuals 18 years of age and older who are at increased risk of exposure to CHIKV. This indication is approved under accelerated approval based on anti-CHIKV neutralizing antibody titers. Continued approval for this indication is contingent upon verification of clinical benefit in confirmatory studies.Valneva: weekly performance: 7.15% Erste Group: Erste Group Bank AG is buying back the 15 % share of its Hungarian subsidiary, Erste Bank Hungary Zrt. (EBH), currently held by the Hungarian state-owned Corvinus International ...Den vollständigen Artikel lesen ...